Q1 Earnings Estimate for BDX Issued By William Blair

Becton, Dickinson and Company (NYSE:BDX) – William Blair issued their Q1 2026 earnings per share estimates for Becton, Dickinson and Company in a research note issued on Thursday, February 6th. William Blair analyst A. Brackmann expects that the medical instruments supplier will earn $3.34 per share for the quarter. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.41 per share. William Blair also issued estimates for Becton, Dickinson and Company’s Q2 2026 earnings at $3.81 EPS, Q3 2026 earnings at $4.04 EPS and Q4 2026 earnings at $4.50 EPS.

Several other research firms have also issued reports on BDX. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler raised their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Stock Down 7.1 %

Shares of NYSE BDX opened at $227.62 on Friday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The business’s 50 day moving average is $231.79 and its two-hundred day moving average is $234.09. The firm has a market cap of $66.01 billion, a price-to-earnings ratio of 38.32, a PEG ratio of 1.80 and a beta of 0.40. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%.

Institutional Investors Weigh In On Becton, Dickinson and Company

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of Jackson Hole Trust acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at about $25,000. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company in the third quarter valued at approximately $26,000. Sierra Ocean LLC acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $29,000. Ashton Thomas Securities LLC purchased a new position in Becton, Dickinson and Company in the 3rd quarter valued at $33,000. Finally, Tompkins Financial Corp increased its stake in Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Shana Carol Neal sold 788 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. This trade represents a 4.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Roland Goette sold 638 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now owns 14,217 shares in the company, valued at $3,113,949.51. This represents a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,844 shares of company stock worth $2,210,716 over the last ninety days. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.83%. Becton, Dickinson and Company’s payout ratio is currently 70.03%.

Becton, Dickinson and Company announced that its board has approved a stock buyback program on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.